Company
Novacyt SA
LON:NCYT
Novacyt SA is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. Novacyt directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
24 stories · page 1 of 2
Novacyt approved for COVID and winter viruses PCR test
The Winterplex 3G assay panel tests for winter viruses such as SARS-CoV-2, influenza A and B, and respiratory syncytial virus (RSV)
Novacyt receives EU approval for saliva-based Covid test
It is one of the first CE mark approvals in the EU for a saliva-based lateral flow self-test for Covid
Novacyt shares slide as DHSC issues a claim against the company
Novacyt said it continues to believe it has strong grounds to defend the claim and assert its contractual rights, including in relation to recovering outstanding sums due from the DHSC
Novacyt has third Covid test approved in UK
Novacyt said it is awaiting further updates on five other products across its COVID-19 testing portfolio
Novacyt says COVID-19 test wins UK approval, pares back revenue shortfall guidance
Shares in the clinical diagnostics specialist surged 15% on the news
Novacyt on the rise again after R&D and UK operational update
Novacyt was a bit slow off the market compared to others, such as Genedrive, to announce its inclusion on the PHE national framework agreement but it is on the list
COVID-19 tests may become more frequent as Boris Johnson suggests rapid assays to open nightclubs
The diagnostics market has yet to peak, according to a broker
Archive
Avacta higher after Bach Biosciences exercises options
A look at some of the major movers in London on Tuesday
Diagnostics sector set to continue to see growth in 2021 and 2022, says broker finnCap
To effective help control the pandemic in the UK alone, it has been suggested the government will need around 120mln tests per month
Investments and investor services
The diagnosis for AIM in 2020 was surprisingly healthy
Hard luck, Orosur Mining. Up 713% on the year and it did not even make the top 10 AIM risers of the year.
Novacyt says its tests can detect new coronavirus strain
A computer simulation analysis showed that its kits were able to detect all published COVID-19 strains with the same level of accuracy
Novacyt’s success shows the power of the first mover advantage
The biotech has seen the value of its share price rocket astronomically in the last year following the release of its coronavirus test in February, with a growth rate of over 8,300%
Anatomy of a winner: picking a coronavirus success stock
While the pandemic has roiled global markets, and society, since March, investors may have found success among the lockdown if they had parked their cash in a number of sectors and industries ahead of the crisis
Novacyt slips as reimbursement for coronavirus test rejected by French regulators
The diagnostics group said it will still be able to sell the test in France for private patient testing
Archive
Trakm8 feeling the effects of the coronavirus lockdown
A look at some of the major movers in London on Monday
Archive
Bank of Ireland with the old one-two: withdrawn guidance and cancelled dividend
A look at some of the major movers in London on Monday